Abstract 458P
Background
Analysis of ctDNA in operable NSCLC for the identification of patients at high risk of relapse could allow tailoring of adjuvant therapy with EGFR tyrosine kinase inhibitors (TKIs). We assessed whether tracking of EGFR mutations in plasma circulating tumor DNA (ctDNA) predicts relapse in completely resected EGFR-mutant NSCLC.
Methods
A prospective cohort of 45 EGFR-mutant stage I-IIIB NSCLC patients, all of whom underwent complete resection of their tumors, had plasma samples for ctDNA analysis taken post-surgery and in follow-up. Cobas EGFR Mutation Test (cobas) was used for tissue genotyping of the baseline tumor biopsy or surgical specimens, and droplet digital PCR (ddPCR) was performed to track the identified EGFR mutations in ctDNA.
Results
We identified EGFR exon 19 deletions (n = 23), L858R (n = 18), and L861Q (n = 4) mutations by cobas in pre-surgical tissue biopsies and/or surgical specimens, and used ddPCR assays for each EGFR mutation to measure ctDNA after surgery. Detection of ctDNA after complete tumor resection in 11 of 45 (24%) patients significantly predicted clinical relapse (hazard ratio [HR] 7.0, 95% confidence interval [CI] 2.13 to 22.68; log-rank p = 0.001). Multivariable analysis demonstrated that detection of ctDNA remained a significant predictor of clinical relapse after adjusting for clinical factors (HR 6.16, 95% CI 1.80 to 21.06; p = 0.004). Notably, ctDNA-based molecular relapse demonstrated a lead time of up to 8.1 months over clinical relapse.
Conclusions
Tracking of EGFR mutations in cfDNA following surgical treatment can identify NSCLC patients at high risk of relapse. Whether ctDNA monitoring could allow tailoring of adjuvant therapy with EGFR tyrosine kinase inhibitors will have to be determined in future clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
M. Filipits: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. M.J. Hochmair: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. A. Buder: Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract